Several recent studies [10–19] have shown that low PINX1 expression is associated with poor survival and different clinicopathological characteristics in various types of cancer, including colorectal cancer, ovarian carcinoma, breast cancer, non-small cell lung cancer, bladder urothelial carcinoma, renal cell carcinoma, and prostate cancer. Here, PINX1 is linked to non-small cell lung carcinoma.